FOLH1 and pachyonychia congenita: According to the evidence currently available, its use is recommended in the initial staging of unfavorable intermediate and high-risk PC, in recurrence and biochemical persistence, in nmCRPC based on conventional imaging modalities, and in patient selection for potential PSMA-targeted therapy [33].